Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
PTC THERAPEUTICS, INC. | Director | Common Stock | 29K | $794K | $27.38 | Jun 9, 2022 | Direct |
Xenon Pharmaceuticals Inc. | Director | Common Shares | 25K | $246K | $9.85 | Aug 24, 2023 | Direct |
ACELYRIN, Inc. | Director | Director Stock Option (right to buy) | 92.2K | Jun 7, 2024 | Direct | ||
Xenon Pharmaceuticals Inc. | Director | Stock Option (Right to Buy) | 15.5K | Jun 5, 2024 | Direct | ||
Adverum Biotechnologies, Inc. | Director | Stock Option (Right to Buy) | 10.5K | Jun 17, 2024 | Direct | ||
Global Blood Therapeutics, Inc. | Director | Common Stock | 0 | $46.99 | Oct 5, 2022 | Direct | |
Global Blood Therapeutics, Inc. | Director | Restricted Stock Units | 0 | Oct 5, 2022 | Direct | ||
Global Blood Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 0 | Oct 5, 2022 | Direct |